2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Transfusion, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1199 From integrin adaptor to tumor gatekeeper: RIAM cell‑intrinsically restrains macrophage M2‑like programming and limits tumor progression

Monisha Kashyap, MD, Anthos Christofides, MD, PhD2, Diya Chaudhary3, Rinku Pal, BS4, Carol Cao5, Vassiliki Boussiotis, MD PhD6
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, The University of Texas MD Anderson Cancer Center, Baltimore, Maryland, United States
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Emmanuel College, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, The Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States
6 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Macrophages are key architects of the tumor microenvironment (TME), where they influence tumor progression through integrin-mediated adhesion, migration, phagocytosis, and modulation of antigen presentation. The Rap1-interacting adaptor molecule (RIAM) is a multidomain protein comprising of a Ras-association–Pleckstrin homology (RA–PH) module, an N-terminal talin-binding region, and C-terminal proline-rich motifs that recruit Ena/VASP and profilin. Together, these domains link Rap1-GTP and PI(4,5)P2 to talin, driving talin recruitment, and serving as a crucial node in inside-out integrin activation. This high-affinity activation of β2-integrins (such as LFA-1 and Mac-1) is essential for leukocyte trafficking, actin remodeling, formation of lamellipodial protrusions that support directional migration, and complement-mediated phagocytosis. Macrophages express high levels of RIAM, positioning this adaptor to support environmental sensing, adhesion, and integrin-dependent effector functions within tissues. Our previous studies have shown that the Rap1/RIAM signaling pathway induces expression of CD103 (integrin αE) in T cells, which heterodimerizes with β7 to form αEβ7. This integrin binds E-cadherin on epithelial cells to direct T cell homing to barrier tissues. Notably, Rap1-mediated CD103/αEβ7 expression also imparted regulatory and immunosuppressive activity in T cells, even in the absence of the canonical T-reg transcription factor FOXP3, highlighting a key link between Rap1-driven integrin programs and immune regulation. The role of RIAM in the myeloid compartment, specifically in tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), remains poorly defined. To investigate this, we generated mice with myeloid-specific RIAM deletion (RIAMfl/fl/LysM-Cre) and implanted MC17-51 fibrosarcoma or B16-F10 melanoma. RIAMfl/fl/LysM-Cre mice developed significantly larger tumors than wild-type controls (WT), indicating that RIAM expression in myeloid cells suppresses tumor growth. Flow cytometry of TAMs revealed a shift toward an M2-like phenotype in RIAM-deficient TAMs, with increased CD206, CD204 and CD163, and reduced CD86, CD88, and MHC-II expression. Transcriptomic analysis showed amplified IL-4/IL-13 signaling, and stunted NF-κB–mediated inflammatory responses, signifying an overall impaired pro-inflammatory and antigen presenting program of TAMs in the absence of RIAM. RIAM-deficient splenic MDSCs, in contrast, exhibited decreased immunosuppressive capacity. These data indicate that despite diminished MDSC suppressive activity, deletion of RIAM in the myeloid compartment accelerated tumor growth by reprogramming TAMs toward a tumor-promoting state. To determine whether RIAM modulates macrophage activation in a cell-intrinsic manner, we generated bone marrow-derived macrophages (BMDM) from WT and RIAMfl/+/LysM-Cre (RIAMhet) mice and differentiated them under baseline (M0), classically activated (M1-like; LPS + IFN-γ), and alternatively activated (M2-like; IL-4) conditions in vitro. RIAMhet BMDM expressed lower CD86 and MHC-II compared to WT BMDM under both M1- and M2-polarizing conditions, indicating attenuated co-stimulatory activation and antigen-presenting capacity. In parallel, we stimulated BMDM from both strains with defined Toll-Like Receptor/Pattern-Recognition Receptor (TLR/PRR) agonists: LPS (TLR4), PAM3CSK4 (TLR1/2), R848 (TLR7), or Zymosan (TLR2/6/Dectin-1) for 24 and 48 hours. RIAMhet BMDM produced less IL-6 and TNF-α than WT BMDM, demonstrating impaired TLR/PRR-driven inflammatory output even with partial RIAM loss. These findings show that RIAM haploinsufficiency cell-intrinsically skews macrophages toward a less inflammatory state, while compromising costimulatory and antigen-presenting capacities, priming to a pro-tumorigenic state. Our results identify RIAM as a key cell-intrinsic regulator of macrophage activation and a critical determinant of TAM reprogramming in the TME. We suggest RIAM-dependent signaling as a novel macrophage checkpoint, and a potential therapeutic target for reversing TAM-mediated tumor progression.
Monisha Kashyap, MD: No relevant conflicts of interest to declare.